<DOC>
	<DOCNO>NCT02032901</DOCNO>
	<brief_summary>To study combination Daclatasvir Sofosbuvir treatment hepatitis C virus ( HCV ) Genotype 3 infection</brief_summary>
	<brief_title>Phase III Daclatasvir Sofosbuvir Genotype 3 Chronic HCV</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Key Subjects must able understand agree comply prescribe dose regimen procedure , report regularly schedule study visit , reliably communicate study personnel adverse event concomitant medication Subjects chronically infect hepatitis C virus ( HCV ) genotype 3 Subjects HCV treatmentnaive Subjects HCV treatmentexperienced ( previous exposure nonstructural 5A inhibitor prohibit ) HCV RNA â‰¥10,000 IU/mL screen Key HCV Genotypes genotype3 infection ; mixed genotype infection permit Liver organ transplant ( include hematopoietic stem cell transplant ) cornea hair Current known history cancer ( except situ carcinoma cervix adequately treat basal squamous cell carcinoma skin ) within 5 year prior screen Documented suspect hepatocellular carcinoma , evidence previously obtain image study liver biopsy ( screen image study/liver biopsy perform ) Evidence decompensated liver disease include , limited , radiologic criterion , history presence ascites , bleed varix , hepatic encephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>